Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes

NCT01711515 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01711515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01711515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2012
Completion date
July 17, 2020
Enrollment
34 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, not otherwise specified, stage ib2 cervical cancer ajcc v6 and v7, stage ii cervical cancer ajcc v7, stage iia cervical cancer ajcc v7, stage iib cervical cancer ajcc v6 and v7, stage iiib cervical cancer ajcc v6 and v7, stage iva cervical cancer ajcc v6 and v7